News | September 03, 2023
BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
UTD2 is the world's first oral epothilone microtubule inhibitor
Nous-209 has been developed using the Nouscom's viral vector platform
From cancer research to diagnostic solutions
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Subscribe To Our Newsletter & Stay Updated
